ACAC The acronym corresponds to the name of Anti-counterfeiting trade agreement on Drugs.
Many versions of anti-counterfeiting trade agreement, negotiations between 10 countries and 26 EU members were filtered and allowed to know the great number of topics, ranging from fake drugs to orders via the Internet. The agreement proposes a new expanded intellectual property protection on behalf of multinational pharmaceutical companies which, combined with border measures, stifle legitimate trade of generic drugs and have a devastating impact on access to medicines in developing countries. It is not uncommon so that all organizations and individuals who work for access to AIDS drugs and disease plaguing Africa which we are most concerned.
This agreement goes against the intention of promoting greater flexibility in intellectual property and encouraging more inventions and innovations. ACAC
threatens access to quality generic drugs, increasing the confusion between the counterfeit and generic drugs. Today, this agreement enables the customs authorities in exporting and transit countries and importers to seize good drugs on the basis that they are or can be forged. And this for violation of the patent. The commitment of the European Union and the Member States regarding universal access to treatment in developing countries will be possible only if access to generic drugs are actually provided.
Africa has many developing countries, this means that if there is willingness to help stand up for themselves can not impose prices and patents on drugs that they can not afford. Aid is to facilitate access to high quality generics and forget multinationals wanting to be more and more rich at the expense of the health of millions of men, women and children who do not have a Euro per day to survive.